塞德斯医疗于欧洲过敏与临床免疫学会年会上,首次展示了其创新双特异性抗体Cdx-622一期临床研究的积极初步人体试验结果。该数据标志着该候选药物在早期人体试验中取得了令人鼓舞的进展。
塞德斯医疗于欧洲过敏与临床免疫学会年会上,首次展示了其创新双特异性抗体Cdx-622一期临床研究的积极初步人体试验结果。该数据标志着该候选药物在早期人体试验中取得了令人鼓舞的进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.